Home
| Final NICE Guidance Recommends Lucentis(R) (Ranibizumab) For Wet AMD, UK (Medical News Today) |
|
|
| Friday, 29 August 2008 | |
|
Novartis Pharmaceuticals UK Ltd (Novartis) welcomed the Final National Institute for Health and Clinical Excellence (NICE) Technology Appraisal Guidance for age-related macular degeneration. NICE guidance recommends Lucentis(R) (ranibizumab) for the treatment of patients with wet age-related macular degeneration (wet AMD). Read more |
| < Prev | Next > |
|---|










